Argenx

Argenx SE is a clinical-stage biotechnology company based in Breda, the Netherlands, specializing in the development of antibody-based therapies for autoimmune diseases, hematology, and cancer. The company's lead product candidate, efgartigimod, has received regulatory approvals for the treatment of generalized myasthenia gravis and is currently being evaluated in Phase 3 trials for immune thrombocytopenia and pemphigus vulgaris, as well as in Phase 2 trials for chronic inflammatory demyelinating polyneuropathy. Argenx is also advancing cusatuzumab in Phase 2 for hematological cancer and has several preclinical products, including ARGX-117 and ARGX-118, targeting autoimmune inflammatory diseases and airway inflammation, respectively. Additionally, the company is collaborating on product candidates such as ARGX-112 and ARGX-115, which are in early clinical stages for skin inflammation and cancer immunotherapy. Argenx has established partnerships with AbbVie and LEO Pharma, alongside collaboration agreements with other biotechnology firms. Founded in 2008, Argenx focuses on leveraging its antibody engineering technology to address unmet medical needs.